Loading...
XAMS
GLPG
Market cap1.53bUSD
Apr 09, Last price  
21.24EUR
1D
-3.98%
1Q
-20.33%
Jan 2017
-65.15%
IPO
199.15%
Name

Galapagos NV

Chart & Performance

D1W1MN
No data to show
P/E
6.61
P/S
5.84
EPS
3.21
Div Yield, %
—
Shrs. gr., 5y
4.82%
Rev. gr., 5y
-3.66%
Revenues
240m
-52.56%
7,777,00011,240,00035,152,00065,936,00076,978,00093,089,000122,410,00095,887,000136,268,000137,699,00069,368,00039,563,000129,517,000127,087,000288,836,000844,986,000478,053,000484,846,000505,280,000239,724,000
Net income
212m
P
-3,589,000-6,541,000-11,335,000-21,948,000-14,584,0003,010,0004,370,000-33,097,000-5,721,000-8,079,00033,211,000-118,410,00054,012,000-115,704,000-29,259,000149,845,000-311,001,000-125,422,000-217,991,000211,697,000
CFO
-406m
L-18.89%
-2,710,000-3,887,000-9,310,000371,000-8,209,0006,303,000-18,573,000-11,991,00064,104,000522,000-75,555,000-114,590,000239,403,000-147,030,000-142,466,0003,208,617,000-427,336,000-503,827,000-500,544,000-405,970,000
Earnings
Apr 30, 2025

Profile

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
URL
https://www.glpg.com/
IPO date
May 06, 2005
Employees
1,233
Domiciled in
BE
Incorporated in
BE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
239,724
-52.56%
505,280
4.21%
Cost of revenue
371,535
766,690
Unusual Expense (Income)
NOPBT
(131,811)
(261,410)
NOPBT Margin
Operating Taxes
9,613
2,844
Tax Rate
NOPAT
(141,424)
(264,254)
Net income
211,697
-197.11%
(217,991)
73.81%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,770
6,695
BB yield
-0.07%
-0.25%
Debt
Debt current
4,652
7,209
Long-term debt
14,540
36,593
Deferred revenue
1,623,599
Other long-term liabilities
1,105,056
27,348
Net debt
(3,678,884)
(4,174,770)
Cash flow
Cash from operating activities
(405,970)
(500,544)
CAPEX
(18,706)
(36,947)
Cash from investing activities
71,186
(1,245,514)
Cash from financing activities
(5,001)
(1,487)
FCF
(113,492)
(280,994)
Balance
Cash
3,684,501
4,094,062
Long term investments
13,575
124,510
Excess cash
3,686,090
4,193,308
Stockholders' equity
58,572
(209,531)
Invested Capital
3,851,646
4,407,383
ROIC
ROCE
EV
Common stock shares outstanding
65,933
65,699
Price
36.99
-10.54%
41.35
-15.99%
Market cap
2,438,862
-10.23%
2,716,654
-15.73%
EV
(1,240,022)
(1,458,116)
EBITDA
(88,169)
(195,844)
EV/EBITDA
14.06
7.45
Interest
1,654
6,967
Interest/NOPBT